158 related articles for article (PubMed ID: 34446063)
1. Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
Wei X; Bai Y; Wang Z; Zheng X; Jin Z; Liu X
Diabetol Metab Syndr; 2021 Aug; 13(1):88. PubMed ID: 34446063
[TBL] [Abstract][Full Text] [Related]
2. Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus.
Mu L; Wang Z; Ren J; Xiong X; Jin Z; Liu X
Diabetol Metab Syndr; 2022 Feb; 14(1):30. PubMed ID: 35164839
[TBL] [Abstract][Full Text] [Related]
3. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Liu X; Men P; Wang B; Cai G; Zhao Z
Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
[TBL] [Abstract][Full Text] [Related]
4. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis.
Huang L; Zhong W; Liang X; Wang H; Fu SE; Luo Z
J Clin Densitom; 2024; 27(1):101455. PubMed ID: 38101289
[TBL] [Abstract][Full Text] [Related]
7. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.
Li Z; Lin C; Zhou J; Cai X; Zhu X; Hu S; Lv F; Yang W; Ji L
Expert Opin Investig Drugs; 2022 Sep; 31(9):957-964. PubMed ID: 35968648
[TBL] [Abstract][Full Text] [Related]
9. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
10. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
11. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
14. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Li R; Wang R; Li H; Sun S; Zou M; Cheng G
Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
[TBL] [Abstract][Full Text] [Related]
15. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
16. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
17. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
Tang Y; Liu J; Hannachi H; Engel SS; Ganz ML; Rajpathak S
Diabetes Ther; 2018 Dec; 9(6):2259-2270. PubMed ID: 30284688
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
Liu D; Jin B; Chen W; Yun P
BMC Pharmacol Toxicol; 2019 Mar; 20(1):15. PubMed ID: 30832701
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
